Alere, Inc.
http://www.alere.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alere, Inc.
China Biotech IPO Drought Lingers But HK Sees First Of 2024
Biotech IPOs on the Chinese mainland have dried up since June 2023 due to regulatory tightening, but Hong Kong is still open to listings of pre-revenue ventures and has seen its first offering of this year.
MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
Attorneys Predict Pandemic-Related Rise In False Claims Allegations
The Department of Justice may soon be busy with allegations of pandemic-related fraud and abuse, attorneys predicted in a recent conference presentation.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Urine-based Testing
- Other Names / Subsidiaries
-
- Axis-Shield plc
- Cholestech Corporation
- Free & Clear, Inc.
- Inverness Medical Innovations Inc.
- US Diagnostics (USD)
- Ostex International Inc.
- Binax, Inc.
- Biosite, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice